Media headlines about The Medicines Company (NASDAQ:MDCO) have been trending very positive recently, AlphaOne reports. The research firm, a unit of Accern, identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Medicines Company earned a news impact score of 0.69 on AlphaOne’s scale. AlphaOne also gave news articles about the company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have impacted AlphaOne Sentiment’s rankings:

Insider Buying and Selling by Quarter for The Medicines Company (NASDAQ:MDCO)

Shares of The Medicines Company (NASDAQ:MDCO) traded down 1.38% during mid-day trading on Friday, hitting $37.09. The company had a trading volume of 1,335,993 shares. The company’s market cap is $2.64 billion. The firm has a 50-day moving average of $42.64 and a 200-day moving average of $43.88. The Medicines Company has a 12 month low of $30.80 and a 12 month high of $55.95.

The Medicines Company (NASDAQ:MDCO) last released its earnings results on Wednesday, April 26th. The company reported ($1.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by $0.31. The business had revenue of $24.20 million during the quarter, compared to analyst estimates of $37.76 million. The Medicines Company had a negative net margin of 91.25% and a negative return on equity of 19.09%. The business’s revenue for the quarter was down 51.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.03) earnings per share. On average, analysts expect that The Medicines Company will post ($5.97) EPS for the current year.

A number of research analysts have recently issued reports on MDCO shares. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of The Medicines Company in a research report on Monday, March 20th. Cowen and Company increased their price objective on The Medicines Company from $39.00 to $61.00 and gave the company an “outperform” rating in a research note on Wednesday, April 19th. ValuEngine downgraded The Medicines Company from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 20th. Oppenheimer Holdings, Inc. initiated coverage on The Medicines Company in a research note on Monday, May 22nd. They issued a “market perform” rating and a $50.00 price objective for the company. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $62.00 price objective on shares of The Medicines Company in a research note on Wednesday, April 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. The Medicines Company currently has a consensus rating of “Buy” and a consensus price target of $54.40.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at

The Medicines Company Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Receive News & Stock Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related stocks with our FREE daily email newsletter.